The U.S. Food and Drug Administration has approved a landmark drug to treat advanced pancreatic cancer, a development expected to significantly improve patient survival. The drug, Rasonque (daraxonrasib), developed by Revolution Medicines, is a once-daily oral tablet that targets multiple forms of the RAS protein — a key driver of tumor growth in most patients with pancreatic adenocarcinoma, a cancer that originates…
